Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHIG9K)

• Drug Name: Beta-D-Mannose Drug Info
• Synonyms: beta-D-Mannopyranose; beta-D-Mannose; beta-Mannose; 7322-31-8; UNII-CUO87O37MT; (2R,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; CUO87O37MT; CHEBI:28563; beta-1,4-Mannan; Epitope ID:137485; (1-> 2)-beta-D-mannan; 4)-beta-D-mannan; AC1L97TQ; SCHEMBL396651; 2)-beta-D-mannopyranan; CHEBI:80962; CHEBI:59573; CHEBI:27857; [2)-beta-D-Manp-(1-> WQZGKKKJIJFFOK-RWOPYEJCSA-N; ZINC3830679; GUP; NE16895; C02209; WURCS=2.0/1,1,0/[a1122h-1b_1-5]/1/; (2RS,3S,4S,5S,6R)-6-(Hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 439680
  ChEBI ID: CHEBI:28563
  CAS Number: CAS 7322-31-8
  TTD Drug ID: DMHIG9K

Molecule-Related Drug Atlas

Drug(s) Targeting Rhodopsin (RHO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[1]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[1]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Influenza Neuraminidase (Influ NA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[4]
Zanamivir	DMFMBZ4	Influenza	1E30-1E32	Approved	[4]
Peramivir	DMNXY5K	Influenza virus infection	1E30-1E32	Approved	[5]
UX-001	DMD2O0L	Hereditary inclusion body myositis	4A41.2	Phase 3	[1]
CS-8958	DM4CSDH	Influenza virus infection	1E30-1E32	Phase 3	[5]
DAS-181	DM0Y8JP	Influenza virus infection	1E30-1E32	Phase 2	[6]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[1]
GS-3435	DMV7JC6	Influenza virus infection	1E30-1E32	Terminated	[7]
BCX-140	DMBJERO	Influenza virus infection	1E30-1E32	Terminated	[8]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[9]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[10]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[12]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[11]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[13]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[12]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[10]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[12]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[15]
Naproxen	DMZ5RGV	Bursitis		Approved	[16]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[17]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[18]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[19]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[20]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[21]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[20]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[22]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[23]

Drug(s) Targeting Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hexafluronium bromide	DMFY307	Spasm	MB47.3	Approved	[24]
MEPTAZINOL	DMPSB8F	Pain	MG30-MG3Z	Approved	[25]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[26]
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[27]
Plasma derived human butyrylcholinesterase	DMF3IBC	Neurotoxicity	NE61	Phase 1	[28]
Protexia	DME1Y9W	Alzheimer disease	8A20	Phase 1	[29]
JES-9501	DMYR3IE	Alzheimer disease	8A20	Phase 1	[30]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[31]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[31]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[1]
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[1]
Influenza Neuraminidase (Influ NA)	TT50QJ3	NRAM_I33A0	Inhibitor	[1]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[1]
Rhodopsin (RHO)	TTH0KSX	OPSD_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
• [3] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [4] Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
• [5] Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
• [6] Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
• [7] US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
• [8] CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.
• [9] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [10] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [11] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [12] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [13] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [14] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [15] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [16] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [17] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [18] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [19] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [21] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [22] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [23] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [24] Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
• [25] Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
• [26] Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
• [27] Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
• [28] Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
• [29] In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
• [30] Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
• [31] A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.